Funds and ETFs Alector, Inc.

Equities

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
5.25 USD +9.15% Intraday chart for Alector, Inc. +3.14% -34.21%
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.25 USD
Average target price
16.22 USD
Spread / Average Target
+208.99%
Consensus
  1. Stock Market
  2. Equities
  3. ALEC Stock
  4. Funds and ETFs Alector, Inc.